Contract Service Directory

ARL Bio Pharma





Company Headquarters

840 Research Parkway, Suite 546
Oklahoma City, OK 73104
United States

Company Description

ARL Bio Pharma is a contract laboratory that provides analytical and microbiological testing to the pharmaceutical industry. Our laboratory provides guidance and test services for all phases of the product lifecycle following USP, FDA, and ICH guidelines. ARL is FDA registered and audited, ISO 17025 accredited and DEA licensed for Schedules I through V.

Contract Service Directory

    Related Content


    • Breaking News | CRO News | Promotions & Moves
      Parexel Adds Experts to Regulatory Consulting Group

      Parexel Adds Experts to Regulatory Consulting Group

      Four new hires from U.S. FDA and MHRA will serve as technical vice presidents
      12.10.19

    • Breaking News | Drug Development | Trials & Filings
      SK Bio Gains FDA Approval for XCOPRI

      SK Bio Gains FDA Approval for XCOPRI

      Marks the first time a Korean company has independently brought a compound from discovery to U.S. FDA approval
      11.25.19


    • Biologics, Proteins, Vaccines | Biosimilars
      Biopharma Over 20 Years

      Biopharma Over 20 Years

      A look at the key trends that have impacted the biopharma industry over the years.
      K. John Morrow, Jr. and Eric S. Langer, BioPlan Associates 11.20.19

    • Validation

    • CPL

      CPL's David Tyler

      CPL's director of business development was on hand at Contract Pharma 2019.
      Contract Pharma


    • cGMP Manufacture | Drug Development
      Contract Pharma’s 20th Anniversary Series: CDMO Insight

      Contract Pharma’s 20th Anniversary Series: CDMO Insight

      JoyL Silva of Pfizer CentreOne discusses global market and regulatory changes driving drug development strategies and the evolution of CDMO services and ops.
      Kristin Brooks, Contract Pharma 11.01.19

    • AAPS Exhibitor List

      ...
      10.29.19



    • Breaking News | Packaging & Tracking | Serialization | Supply Chain
      Barcode Assessment Study Reveals Progress Addressing DSCSA Requirements

      Barcode Assessment Study Reveals Progress Addressing DSCSA Requirements

      GS1 US Barcode Assessment Shows 74% of scanned barcodes meet serialization requirements.
      10.24.19

    • Clinical Trials | Serialization | Supply Chain
      Anti-Counterfeiting in the Pharmaceutical Industry: An Evolution

      Anti-Counterfeiting in the Pharmaceutical Industry: An Evolution

      Keeping up with counterfeitors in the pharmaceutical industry is no easy task, but patients’ lives depend on it.
      Ben Locwin, Healthcare Science Advisors 10.04.19

    • Regulatory Affairs
      Quality Metrics Feedback

      Quality Metrics Feedback

      A look at FDA’s Quality Metrics Initiative, a complicated issue for all of pharma stakeholders
      Gil Roth, President, Pharma & Biopharma Outsourcing Association 09.16.19


    • Breaking News | Clinical Trials | Industry News | Inspections | QA/QC
      FDA Extends CRADA with CluePoints

      FDA Extends CRADA with CluePoints

      Aims to further explore a data-driven approach to quality oversight in clinical trials
      09.11.19

    • cGMP Manufacture | Collaborations & Alliances
      NIIMBL, FDA to Advance Innovation in Bio Manufacturing

      NIIMBL, FDA to Advance Innovation in Bio Manufacturing

      CRADA enables FDA and NIIMBL to support investments in regulatory science research, and training needed to foster advanced manufacturing innovations
      08.01.19

    • Packaging & Tracking | Serialization | Supply Chain
      TraceLink, Excellis Partner to Provide Local Track and Trace Services in Russia

      TraceLink, Excellis Partner to Provide Local Track and Trace Services in Russia

      Aims to help pharma companies engage with local Russia teams and comply with Russian track and trace requirements
      07.18.19

    • Trials & Filings
      FDA Accepts RedHill Biopharma’s NDA for Talicia

      FDA Accepts RedHill Biopharma’s NDA for Talicia

      Commercial launch of H. pylori treatment is planned shortly following potential FDA approval
      07.16.19

    • Extractables and Leachables | Laboratory Testing
      The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up?

      The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up?

      Andrew Kolbert of Avomeen discusses FDA oversight of E&L testing, complications that arise, and the expertise needed to keep up with changing quality standards
      Kristin Brooks, Contract Pharma 07.11.19